IN THE CLAIMS:

Cancel claims 1-86, without prejudice.

Add new claims 87-115 as follows.

1.-86. (Canceled)

87. (New) A modified IgG comprising a human IgG constant domain comprising one or more amino acid substitutions relative to a wild-type human IgG constant domain at one or more amino acid residues 251-256, 285-290, 308-314, 385-389 and 428-436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein an amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine, an amino acid substitution at amino acid residue 254 is a substitution with threonine, an amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamate, asparate, alanine, asparagine or threonine, an amino acid substitution at amino acid residue 309 is a substitution with proline, an amino acid substitution at amino acid residue 311 is a substitution with serine, an amino acid substitution at amino acid residue 433 is a substitution with lysine, arginine, serine, isoleucine, proline, glutamine or histidine, and an amino acid substitution at amino acid residue 434 is a substitution with histidine, asparagine, arginine, threonine, lysine or methionine.

88. (New) A modified IgG comprising a human IgG constant domain comprising amino acid substitutions relative to a wild-type human IgG constant domain at amino acid residues 252, 254 and 256, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, the amino acid substitution at amino acid residue 254 is a substitution with threonine, and the amino acid substitution at amino acid residue 256 is a substitution with glutamate.

89. (New) A modified IgG comprising a human IgG constant domain comprising amino acid substitutions relative to a wild-type human IgG constant domain at amino acid residues 433, 434 and 436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the amino acid substitution at amino acid residue 433 is a substitution with lysine, the amino acid

substitution at amino acid residue 434 is a substitution with phenyalanine, and the amino acid substitution at amino acid residue 436 is a substitution with histidine.

90. (New) A modified IgG comprising a human IgG constant domain comprising amino acid substitutions relative to a wild-type human IgG constant domain at amino acid residues 252, 254, 256, 433, 434 and 436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, the amino acid substitution at amino acid residue 254 is a substitution with threonine, the amino acid substitution at amino acid residue 256 is glutamate, the amino acid substitution at amino acid residue 433 is a substitution with lysine, the amino acid substitution at amino acid residue 434 is a substitution with phenyalanine, and the amino acid substitution at amino acid residue 436 is a substitution with histidine.

91. (New) A modified IgG comprising a non-human IgG constant domain comprising one or more amino acid substitutions relative to a wild-type non-human IgG constant domain at one or more amino acid residues 251-256, 285-290, 308-314, 385-389 and 428-436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type non-human IgG constant domain, and wherein an amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine, an amino acid substitution at amino acid residue 254 is a substitution with threonine, an amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamate, asparate, alanine, asparagine or threonine, an amino acid substitution at amino acid residue 309 is a substitution with proline, an amino acid substitution at amino acid residue 311 is a substitution with serine, an amino acid substitution at amino acid residue 433 is a substitution with lysine, arginine, serine, isoleucine, proline, glutamine or histidine, and an amino acid substitution at amino acid residue 434 is a substitution with histidine, asparagine, arginine, threonine, lysine or methionine.

92. (New) The modified IgG of claim 87, 88, 89, 90 or 91 which has a higher affinity for FcRn than the IgG having the wild-type constant domain.

93. (New) The modified IgG of claim 87, wherein an amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine or glycine, an amino acid substitution at amino acid residue 386 is a

substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine, an amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine, or alanine, an amino acid substitution at amino acid residue 389 is a substitution with proline, serine or asparagine.

94. (New) The modified IgG of claim 91, wherein an amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine or glycine, an amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine, an amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine, or alanine, an amino acid substitution at amino acid residue 389 is a substitution with proline, serine or asparagine.

95. (New) The modified IgG of claim 87, 88, 89, 90 or 93 which is a human or humanized IgG.

96. (New) The modified IgG of claim 95 which is IgG_1, IgG_2, IgG_3 or IgG_4.

97. (New) The modified IgG of claim 91 or 94 which is a non-human IgG.

98. (New) The modified IgG of claim 97 which is IgG_1, IgG_{2a}, IgG_{2b}, IgG_{2c} or IgG_3.

99. (New) The modified IgG of claim 87, wherein the IgG constant domain is an IgG_1 constant domain.

100. (New) The modified IgG of claim 88, 89, 90 or 93, wherein the IgG constant domain is an IgG_1 constant domain.

101. (New) The modified IgG of claim 87, 88, 89, 90 or 93, wherein the IgG constant domain is an IgG_1, IgG_2, IgG_3 or IgG_4 constant domain.

102. (New) The modified IgG of claim 99, wherein an amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine, an amino acid substitution at amino acid residue 254 is a substitution with threonine, an amino acid substitution at amino acid residue 256 is a substitution with serine,

arginine, glutamine, glutamate, asparate, alanine or asparagine, an amino acid substitution at amino acid residue 309 is a substitution with proline, an amino acid substitution at amino acid residue 311 is a substitution with serine, an amino acid substitution at amino acid residue 433 is a substitution with lysine, arginine, serine, isoleucine, proline or glutamine, and an amino acid substitution at amino acid residue 434 is a substitution with histidine, arginine, threonine, lysine or methionine.

103. (New) The modified IgG of claim 102, wherein an amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine or alanine, an amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine, an amino acid substitution at amino acid residue 387 is a substitution with arginine, histidine, serine, threonine, or alanine, an amino acid substitution at amino acid residue 389 is a substitution with proline or serine.

104. (New) The modified IgG of claim 97 which is a rodent, donkey, sheep, rabbit, goat, guinea pig, camel, horse or chicken IgG.

105. (New) The modified IgG of claim 91, wherein the non-human IgG constant domain is a rodent, donkey, sheep, rabbit, goat, guinea pig, camel, horse or chicken IgG constant domain.

106. (New) The modified IgG of claim 87, 88, 89, 90, 91, 93, 94, 102 or 103 which immunospecifically binds to an RSV antigen.

107. (New) The modified IgG of claim 87, 88, 89, 90, 93, 102 or 103 which has the heavy chain variable domain and light chain variable domain of palivizumab.

108. (New) The modified IgG of claim 87, 88, 89, 90, 93, 102 or 103 which has the heavy chain variable domain and light chain variable domain of A4B4L1FR-S28R (SEQ ID NOS.:48 and 11).

109. (New) A pharmaceutical composition comprising the modified IgG of claim 87, 88, 89, 90, 91, 93, 94, 102 or 103 and a pharmaceutically acceptable carrier.

110. (New) A pharmaceutical composition comprising the modified IgG of claim 106 and a pharmaceutically acceptable carrier.

111. (New) A pharmaceutical composition comprising the modified IgG of claim 107 and a pharmaceutically acceptable carrier.

112. (New) A pharmaceutical composition comprising the modified IgG of claim 108 and a pharmaceutically acceptable carrier.

113. (New) A kit comprising the modified IgG of claim 87, 88, 89, 90, 91, 93, 94, 102 or 103, in a container, and instructions for use.

114. (New) A kit comprising the modified IgG of claim 106, in a container, and instructions for use.

115. (New) A kit comprising the modified IgG of claim 107, in a container, and instructions for use.

116. (New) A kit comprising the modified IgG of claim 108, in a container, and instructions for use.